Welcome back to Stockhouse
Member Sign In

Email or Username:

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Get our best content in your email.

You are already a member! Please enter your password to sign in.
Quote  |  Bullboard  |  News  |  Opinion  |  Level II  |  Charts  |  Profile  |  Financials  |  Options  |  Price History  |  Analysts  |  Earnings  |  Insiders

AEterna Zentaris Inc T.AEZ

Sector: Healthcare | Sub-Sector: Biotechnology
Alternate Symbol(s):  AEZS

AEterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing novel treatments in oncology, endocrinology and women's health.
Price: $0.12 Volume: 1.2m
Change: +$0.005 % Change: +4.35%
Day High/Low: 0.125/0.115 52 Week High/Low: 1.54/0.065
Last Traded: October 06, 2015 11:54 Transaction Volume: 120
Open: 0.115 Previous Close: 0.115
Bid: 0.12 Ask: 0.125
Bid Size: 10000 Ask Size: 118000
Market Cap: 59.1m Shares Out: 492.5m
PE Ratio: N/A Dividend Yield: N/A

Latest Bullboard Posts

  • AEZ::: University of Texas Southwestern Medical Center:

    5 stars

    University of Texas Southwestern Medical Center: "Recently, UT Southwestern participated in a study of a drug called zoptarelin...

    2.5 stars

  • tomorrow should be fun here

    5 stars

    crazy day on Friday, and tons of chatter on every stock board on the internet. I bought this on the way down, unfortunatley not at 0.07...

    1.5 stars

  • Here is the correct description now.

    3 stars

    Developing Products for Rare Diseases & Conditions   The FDA Office of Orphan Products Development (OOPD) mission is to...

    4.5 stars

  • Orphan Drug Status

    3 stars

    "Zoptarelin doxorubicin has been granted orphan-drug designation by the FDA". Orphan Drug Status is for drugs that treat...

    2 stars

  • Insiders buying

    1 star Insiders have been heavily buying shares in...

    1 star